Update on Remdesivir in the Treatment of Novel Coronavirus Pneumonia by Huang Feng, K. Vijaya Lakshmi, Chin Tat Ng, Murthy Sasikumar, Masita Arip, Masriana Hassan, Voon Kin Chin, Mogana Rajagopal, Omotayo Fatokun, N. Parvathi, Malarvili Selvaraja

“…Remdesivir has maintained high inhibitory activity against all existing SARS-CoV-2 variants, including the Omicron variant. …”
Get full text

Repetitive stability study of remdesivir/cyclodextrin complex on the international space station by György Dormán, Balázs Buchholcz, István Puskás, Pál Szabó, Erzsébet Varga, Lajos Szente, György M. Keserű, Ferenc Darvas

Subjects: “…Remdesivir sulfobutylether-beta-cyclodextrin…”
Get full text

Remdesivir-induced severe hypoglycemia in an elderly man without diabetes: a case report by Yasunori Nagano, Hisae Aoki, Juri David, Naoko Iwahashi Kondo, Makimi Aizawa, Toshiyuki Sumita, Yuki Hamada, Yuki Yamamoto, Kaoru Yamada

Subjects: “…Remdesivir…”
Get full text

Severe Bradycardia Leading to Hemodynamic Instability Associated with Remdesivir Use in a Patient with COVID-19 Pneumonia by Bhargavi Donepudi, Shikhar Agarwal, Lokendra Thakur

“…Remdesivir (RDV) is an approved treatment for hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. …”
Get full text

Acute Generalized Exanthematous Pustulosis following SARS-CoV-2 Virus: Remdesivir as a Suspected Culprit by Fatemeh Mohaghegh, Parvaneh Hatami, Zeinab Aryanian, Farahnaz Fatemi, Zeinab Mohseni Afshar

“…We, hereby, present the first case of AGEP following treatment with remdesivir in a patient with COVID-19, without hydroxychloroquine use, which serves as a reminder to consider remdesivir as a possible causative agent when dealing with AGEP presentation in COVID patients.…”
Get full text

Predictive factors associated with short‐term mortality in cats with feline infectious peritonitis treated with remdesivir or GS‐441524 or both by Sho Goto, Tsuyoshi Kamiyoshi, Ryota Iwasaki

“…Abstract Background Although most cats with feline infectious peritonitis (FIP) respond to treatment with remdesivir or GS‐441524 or both with uneventful clinical courses, some die despite treatment. …”
Get full text

Clinical outcomes of early remdesivir administration in hospitalized patients at high risk for severe COVID-19 during the Omicron wave by Yeon Ju La, Won Sup Oh, Changhyup Kim, Myoung-nam Lim, Yong Duk Jeon

Subjects: Get full text

The evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality during the 2023–2024 phase of JN.1 subvariant dominance by Drieda Zaçe, Albiana Çekrezi, Christopher Jones, Ludovica Ferrari, Giuseppe De Simone, Elisabetta Teti, Vincenzo Malagnino, Marco Iannetta, Loredana Sarmati, Anna Maria Geretti

Subjects: Get full text

Current strategies in diagnostics and therapeutics against novel coronavirus disease (COVID-19) by ALOTAIBI FAISAL

Subjects: Get full text

Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies by Daoud Safa, Alabed Shada J., Dahabiyeh Lina A.

Subjects: Get full text

Capture réglementaire en temps de pandémie by Samira Guennif

“…In the midst of the covid-19 pandemic, the Food and Drug Administration (FDA) published in March the orphan drug status granted to remdesivir, a molecule patented by Gilead as a treatment for the new coronavirus. …”
Get full text

Evaluation of COVID-19 protease and HIV inhibitors interactions by Tran Linh, Tam Dao Ngoc Hien, Elhadad Heba, Hien Nguyen Minh, Huy Nguyen Tien

“…The comparison of the binding sites of three drugs, namely, darunavir, atazanavir and remdesivir, showed an overlap region of the protein pocket. …”
Get full text

Co-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus HKU1 (HCoV-HKU1) by Laszlo Madaras, Radean Anvari, Claudia Schuchardt-Peet, Abhinav Hoskote, Rahul Kashyap

“…Providers should be cautious with the use of remdesivir in cases of co-infection and in severely ill COVID-19 patients who have a history of atrial fibrillation.…”
Get full text

COVID-19 Infection Clinical Profile, Management, Outcome, and Antibody Response in Kidney Transplant Recipients: A Single Centre Experience by Sanjiv Jasuja, Gaurav Sagar, Anupam Bahl, Shalini Verma

“…The treatment options and used were steroids (100%), convalescent plasma (32.8%), ivermectin (58.2%), doxycycline (55.2%), remdesivir (34.3%), tocilizumab (10.4%), antibiotics (61.2%), anti-fungals (26.9%), low molecular weight heparin (45.3%), and oral anti-coagulants (26.9%). …”
Get full text

Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review by Nidhi Garg, Ananya Sree Kunamneni, Pankaj Garg, Sandeep Sharma, Divakar Sharma, Adinarayana Kunamneni

“…The third choice is remdesivir if sotrovimab is also not available and molnupiravir is to be given if the other three options are not available or cannot be administered. …”
Get full text

Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report by Yuki Miyata, Ryo Yamaguchi, Takehito Yamamoto, Toshiyuki Kishida, Kazuhiko Ikeuchi, Hiroaki Harada, Takeya Tsutsumi, Keishi Fujio, Tappei Takada

“…Considering persistent COVID-19, we initiated combination therapy with remdesivir and ensitrelvir (day 0). TAC was discontinued, and the TAC blood levels decreased from 3.6 ng/mL to 1.1 ng/mL over five days. …”
Get full text

COVID-19: An Update on the Latest Therapeutic Agents by Ke-Yan Loo, Loh Teng-Hern Tan, Jodi Woan-Fei Law, Kar-Wai Hong, Kok-Gan Chan, Vengadesh Letchumanan

“…Existing drugs such as remdesivir, molnupiravir, baricitinib, anakinra, and tocilizumab have been repurposed to treat COVID-19 earlier during the pandemic to meet the urgent demand for treatment. …”
Get full text

Assessment of asymptomatic fungal infections in COVID-19 positive and COVID-19 negative pneumonia: A comprehensive epidemiological analysis by Dheerendra Kumar Mishra, Pramod Kushwaha, Pooja Gangwar, Ajeet Singh, Umesh Pratap Singh

“…Furthermore, COVID-19-positive patients exhibited distinct clinical characteristics, including increased use of remdesivir (94%), higher rates of invasive mechanical ventilation (36%), and a prolonged hospital stay (14.29 days). …”
Get full text

Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection. by Bryce M Warner, Robert Vendramelli, Amrit S Boese, Jonathan Audet, Nikesh Tailor, Courtney Meilleur, Nathan Glowach, Marnie Willman, Thang Truong, Estella Moffat, Kevin Tierney, Beata Kosak, Irfan Dhanidina, Jarret Engstrom, Bozena Korczak, Ian McGowan, Carissa Embury-Hyatt, Darwyn Kobasa

“…Daily treatment with OB-002 altered immune gene transcription in the lungs, and reduced pathology following infection, but did not prevent weight loss or viral replication in the lungs of infected animals, even in combination with the antiviral drug remdesivir. Our data suggest that targeting the CCR5-CCL5 pathway in SARS-CoV-2 infection in hamsters is insufficient to significantly impact disease development in this model.…”
Get full text

Antivirals for the treatment of mild and moderate COVID-19 in South Africa by R Perumal, V Naidoo, S Govender, T N Gengiah

“…COVID‐19 antivirals such as remdesivir, nirmatrelvir/ ritonavir and molnupiravir are safe and cost‐effective and have received either full approval or emergency use authorisation from regulators. …”
Get full text